by: Parent Project Muscular DystrophyDomagrozumab as a Potential Treatment for Duchenne (May 2019)
On May 22, 2019, Pfizer Inc. joined Parent Project Muscular Dystrophy for a webinar to provide the community with an overview of the primary safety and efficacy results from the Phase 2 clinical trial. Additional details are provided on the on secondary efficacy endpoints and imaging results.
